HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2006; **21**: 575–576.

Author Index

Abbate-Daga, G., 181
Agrawal, N., 447
Ahlner, J., 151
Akgoz, S., 337
Aki, H., 439
Akkaya, C., 337
Akyol, O., 53
Al-Din, A. S., 489
Alquier, C., 139
Anderson, C., 299
Antonijoan, R., 13
Aono, M., 439
Aschauer, H., 61

Back, S. E., 377
Baldessarini, R. J., 189
Barbanoj, M. J., 13
Barrett, S. P., 255
Bengtsson, F., 151
Bertelli, M., 73
Blin, O., 139
Brady, K. T., 377
Brown, G. G., 101
Brustolin, A., 181
Bryan, J., 27
Buchanan, T., 285
Bueno, O. F. A., 327
Burns, N. R., 27
Byrne, A., 63

Caetano, S. C., 215
Campisi, S., 181
Cassidy, E. M., 265
Castellani, A., 73
Centorrino, F., 189
Cerri, G. G., 215
Chae, B.-J., 387
Cho, J.-Y. 519
Cho, M.-J., 387
Choi, S.-K. 533
Clark, E., 127
Clark, T., 189
Collie, A., 481
Conley, R. R., 393
Cotton, S., 511
Croft, R. J., 47
Curran, S., 1

Dahl, M.-L., 151
Darekar, M. A., 481
Darredeau, C., 255
Davies, L., 447
de Castro, C. C., 215
de M. S. Amaral, J. A., 215
Donado, E., 13
Doshi, R., 39

Earleywine, M., 455
Egli, S., 189
Eker, S. S., 337
Erös-Sarnyai, M., 549

Fakra, E., 139
Farabaugh, A. H., 221
Fassino, S., 181
Fava, M., 221
Fisk, J. E., 355

Galduróz, J. C. F., 327
Gallinat, J., 463
García-Gea, C., 13
Gillman, P. K., 117
Gonen, N., 235
Gorynia, I., 463
Green, C., 539
Guerdjikova, A., 425
Gulec, M., 53

Habil, H., 313
Han, C.-S., 399
Hatim, A., 313
Hatsukami, D., 539
Heffernan, T., 285
Heinz, A., 463
Hennen, J., 189
Herken, H., 53
Hewlett, P., 167
Hill, K. P., 367
Hori, H., 433
Horne, J. A., 299
Huggins, J. P., 481
Hwang, G., 319

Iga, J., 439
Ikenouchi, A., 433
Isohanni, M., 195
Issler, C. K., 215
Izquierdo, I., 13

Jambunathan, S. T., 313
Jané, F., 13
Jang, I.-J. 519
Jesjeet, S. G., 313
Joe, S.-H., 399
Joseph, J., 313
Jouve, E., 139
Juckel, G., 463
Jung, I.-K., 399

Kalenderoglu, A., 53
Kaneda, Y., 439
Kang, B.-J., 387
Kasper, S., 61
Keck, Jr., P. E., 425
Kelly, D. L., 393
Kim, E., 519
Kim, G.-H., 319
Kim, H.-G., 409
Kim, H.-R., 319
Kim, J.-W., 409
Kim, S.-H., 319, 399
Kim, S.-W. 533
Kim, Y. G., 409
Kim, Y., Y. 519
Kinouchi, S., 439
Kiosseoglou, G., 305
Kirli, S., 337
Ko, J., 387
Ko, Y.-H., 399
Koponen, H., 195
Koren, A., 227
Kotwal, R., 425
Kounti, F., 305
Kozman, M. N., 1
Kupchik, M., 235
Kwon, J. S., 519

Lafer, B., 215
La Malfa, G., 73
Langer, S., 473
Lassi, S., 73
Le Guern, M.-E., 139
Lee, J.-H., 399
Lee, M.-S., 399
Lee, S.-H., 399
Lee, S.-Y., 409
Lee, T. H., 367
Lee, Y., 387
Leombruni, P., 181
Leonard, B. E., 205, 273, 413, 414, 489
Levi, M., 181
Ling, J., 285
Looby, A. R., 549
Low, C. C., 313
Lukas S. E., 549
Lundahl, L. H. 549

Copyright © 2006 John Wiley & Sons, Ltd.

Mallya, G., 189
Mannelli, P., 367
Marozio, S., 181
Maruff, P., 481
Matsushita, M., 439
Maximova, N. M., 109
McElroy, S. L., 425
McGorry, P. D., 511
McNamara, B., 265
McNeil, J. F., 549
McRae, A. L., 377
Melkersson, K. I., 529
Mester, R., 235
Micallef, J., 139
Miettunen, J., 195
Mischoulon, D., 221
Misionzhnik, E. Y., 109
Mondelli, V., 181
Montgomery, C., 355
Mooney, M., 539
Mulert, C., 463
Mullins, G. M., 265
Murphy, B. P., 511
Murphy, P. N., 355

Nakamura, J., 433
Nakano, Y., 433
Nathan, P. J., 47
Nettelbeck, T., 27
Netter, K. J., 560
Netter, P., 91, 560
Nguyen, N., 139
Nieminen, P., 195
Nogueira, A. M. L., 327

O'Neill, B., 47
O'Sullivan, S. S., 265
Ochoa, E. L. M., 127
Odén, A., 151
Oh, J.-T., 387
Ohmori, T., 439
Ortner, R., 61
Ozen, M. E., 53

P. Netter, 560
Pae, C., 367
Pannet, I., 227
Papakostas, G. I., 221
Park, S.-H., 319
Park, S.-R., 319
Parrott, A. C., 285
Patkar, A. A., 367
Pedrelli, P., 221
Peindl, K., 367
Penetar, D. M., 549
Pérez, I., 13
Phan, K. L., 47
Pierò, A., 181
Pihl, R. O., 255
Pjrek, E., 61
Pompéia, S., 327
Pradel, V., 139
Prochazka, J., 151

Ramaekers, J. G., 473
Rich, J. B., 101
Richardson, C. M., 393
Robertson, M. M., 447
Rodgers, J., 285
Roitman, S., 235

Saladin, M. E., 377
Sampuran, A. K., 39
Savas, H. A., 53
Scholey, A. B., 285
Schwartz, F., 221
Schwartz, S., 235
Segrave, R., 47
Seo, Y.-J., 399
Shin, H.-Y., 159
Shin, I.-S., 159
Shin, S.-G., 519
Shin, Y.-W. 519
Sirota, P., 227
Sivrioglu, E. Y., 337
Sjödin, I., 151
Smith, A. P., 503
Smith, A., 167
Snyder, P. J., 481
Solans, A., 13
Sonawalla, S. B., 221
Spivak, B., 235
Stern, J. S., 447
Strous, R. D., 235
Stuart, A. H. 511
Su, Z., 549
Sumitani, S., 439
Sundram, S., 245
Svoboda, E., 101

Tamada, R. S., 215
Taniguchi, K., 439
Taniguchi, T., 439
Tchernichovsky, E., 227
Thomas, M. A., 503
Timmerman, M. A., 377
Tomotake, M., 439
Tsolaki, M., 305
Tsolaki, M., 305
Tsuno, M., 439
Tutkun, H., 53

Ueda, N., 433
Uhl, I., 463
Upadhyaya, H., 377
Ussher, M., 39
Uzbekov, M. G., 109

Vertogradova, O. P., 109

Wålinder, J., 151
Wade, D., 511
Wareing, M., 355
Wattis, J. 1
Weizman, A., 235
West, R., 39
Wingen, M., 473
Winkler, D., 61
Wutzler, A., 463

Yamanishi, K., 439
Yilmaz, H. R., 53
Yoo, S. Y., 519
Yoon, J.-S., 159
Yoon, J.-S. 533
Yoshimura, R., 433
Yu, K.-S. 519
Yu, Y., 393

Zuraida, N. Z., 313

Copyright © 2006 John Wiley & Sons, Ltd.

HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2006; **21**: 577–578.

Keyword Index

3-methoxy-4-hydroxyphenylglycol (MHPG), 433
5-HT, 367
9-hydroxyrisperidone, 529

ACTH, 377
addiction, 255
adenosine deaminase, 53
adherence, 533
ADHES, 533
adjustment disorders with anxiety, 139
adverse event, 481
agranulocytosis, 387
alcohol, 13, 159, 377
ALDH2, 159
antidepressant medication, 503
antipsychotic agent, 529
antipsychotics, 73
anxiety, 337
anxious depression, 109
aripiprazole, 447, 519
arousal, 101
assessment, 305
attention, 101
atypical antipsychotic, 235
atypical antipsychotic, 511

behavioral test of everyday functioning, 305
behavioural disturbance, 1
benzodiazepine, 319
benzodiazepines, 101, 327
benztropine, 549
binge eating disorder, 181, 425
biochemical profiles, 109
biological marker, 47
bipolar disorder, 189, 215, 319, 425, 433
bipolar mania, 313
brain-derived neurotrophic factor (BDNF), 433
bromperidol, 409

caffeine consumption, 167
caffeine withdrawal, 167
Caffeine, 167
cannabis, 245, 255, 355, 455
cetirizine, 13
challenge tests, 91
Chronic Fatigue Syndrome, 503
cigarette cravings, 39
cingulate gyrus, 215
citalopram, 47, 463
clinical trials, 195
clozapine, 235, 387, 393
cocaine, 255, 367, 549
cognition, 13, 245, 285, 481
cognitive abilities, 27
cognitive factors, 221
cognitive functioning, 355
cognitive performance, 167
cogstate, 481
comorbidity, 189
contingency management, 539
cortisol, 377
CYP2D6, 519

daily life activities, 305
defensive medicine, 265
Dementia, 1
depression with anxiety features, 337
depression, 91, 221, 337
diazepam, 101
differential item functioning, 455
dipole source analysis, 463
diurnal patterns, 539
dopamine, 91, 255
DRD2 Taq1A, 519
drug treatments, 1
drugs, 181

eating disorders, 181
Ecstasy, 285, 355
efficacy, 227
electroencephalogram, 265
electrophysiology, 47
episodic memory, 327
escitalopram, 473
etifoxine, 139
event related potential, 47
executive function, 305
exercise, 285

first-episode, 511

gender, 393
general practice setting, 139
genetic polymorphism, 409
Ginkgo biloba, 27

healthy volunteers, 13
heat, 285
high dose, 393
homovanillic acid (HVA), 433
HPA axis, 377
hydroxyzine, 13
hyperprolactinemia, 529

intellectual disability, 73
interaction, 13
isometric exercise, 39

lapses, 299
LDAEP, 47, 463
lithium, 425
long-acting injection risperidone, 399
lorazepam, 139
loudness dependence auditory evoked potential, 47

m-CPP, 367
maintenance, 319
major depression, 151, 245
marijuana, 455
MDMA, 285
medication, 533
memory, 101, 285
meta-analysis, 195
methylphenidate, 255
mianserin, 117
midazolam, 481
mirtazapine, 117, 151, 473
mood disorders, 215
mood, 27, 167

NAA, 215
naturalistic study design, 151
naturalistic, 235
negative symptoms, 227, 511
neurodevelopment, 245
neuroimaging, 215
neutropenia, 387
nicotine replacement, 539
nicotine, 255
nitric oxide, 53

obesity, 181
obsessive-compulsive disorder, 189
office visits, 319
olanzapine, 227, 235, 393
older adults, 27
outcome, 189

p300, 159

Copyright © 2006 John Wiley & Sons, Ltd.

Panic Disorder, 53
PANSS, 399
patient compliance, 319
perceived functioning, well-being, 399
perceived stress, 221
pharmacokinetic, 409
pharmacokinetics, 13
pharmacotherapy, 549
Phase I, 481
physiological effects, 549
plasma level, 393
polydrug, 255
PPR, 221
primary, 511
prolactin peak, 91
prospective memory, 101
proton magnetic resonance spectroscopy, 215
psychiatry, 265
psychomotor performance, 13, 159
psychopharmacology, 195
PTSD, 377

QEEG, 519
quality of life, 439
quetiapine, 227, 313, 439

rapid titration, 313
reaction time, 299
reboxetine, 337
recovery, 503
recurrence, 319
replacement, 439
review, 73
risperidone, 235, 433
risperidone, 529
rupatadine, 13

safety, 227
schizophrenia, 227, 235, 245, 265, 399, 439, 511, 533
schizotypal personality, 455
schizotypy, 455
sedation, 481
seizure, 265
selection bias, 151
selective serotonin reuptake inhibitor, 47
semantic facilitation, 327
sensation seeking, 91
serial position curve, 327
serotonin toxicity, 117
serotonin, 47, 367, 463, 473
serotonin, dual action, 117
sertraline, 109, 181
sex, 393
side effect, 529
sleepiness, 299
smoking cessation, 39, 539
smoking topography, 539
smoking, 393
soft drinks, 299
SSRI, 463
statistical methodology, 195
statistical software, 195
stress, 377
subjective effects, 13
subjective response, 159
substance abuse, 367
substance use disorders, 245
superoxide dismutase, 53

TDR, 221
tianeptine, 109
time of response, 91
tobacco withdrawal, 39
topiramate, 425
Tourette Syndrome, 447
treatment response, 53
treatment, 337, 447

venlafaxine, 337
verbal memory, 473
visual analog scales, 549

weight loss, 425

xanthine oxidase, 53

young adults, 27

Copyright © 2006 John Wiley & Sons, Ltd.

Human Psychopharmacology
Clinical and Experimental

CO-EDITORS

Professor Stephen Curran
Wakefield, UK
steve.curran@swyt.nhs.uk

Professor C. Lindsay DeVane
Charleston, USA
devanel@musc.edu

EDITORIAL BOARD

Professor Hervé Allain
Rennes, France

Prof. Dr. Christer Allgulander
Huddinge, Sweden

Dr. David Baldwin
Southampton, UK

Dr. Manel Barbanoj de Rodriguez
Barcelona, Spain

Professor Michael Berk
Geelong, Australia

Professor Michael Bourin
Nantes, France

Professor Ted Dinan
Cork, Ireland

Professor Helmut Erzigkeit
Erlangen, Germany

Dr. Peter Haddad
Manchester, UK

Professor Brian H. Harvey
Potchefstroom, South Africa

Professor Yul Iskandar
Jakarta Pusat, Indonesia

Professor Jan M. Keppel-Hesselink
Witten, Germany

Professor Brian E. Leonard
Galway, Ireland

Professor Toshitaka Nabeshima
Nagoya, Japan

Professor Pradeep J. Nathan
Hawthorn, Australia

Professor Petra Netter
Giessen, Germany

Professor Trevor Norman
Heidelberg, Australia

Professor Gregory Oxenkrug
Boston, USA

Professor Andy Parrott
Swansea, UK

Professor Wim Riedel
Cambridge, UK

Professor Bernd Saletu
Vienna, Austria

Professor Jair C. Soares, MD
San Antonio, USA

Professor Peter Stonier
Richmond, UK

Professor Kazuhiko Yanai
Sendai, Japan

Professor Lakshmi Yatham
Vancouver, Canada

Professor Allan H. Young
Newcastle-upon-Tyne, UK

AIMS AND SCOPE

Human Psychopharmacology provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of especial interest to the editors and readers of the journal:

- All aspects of clinical psychopharmacology
- Efficacy and safety studies of novel and standard psychotropic drugs
- Studies of the adverse effects of psychotropic drugs
- Effects of psychotropic drugs on physiological processes
- Geriatric and Paediatric psychopharmacology
- Ethical and psychosocial aspects of drug use and misuse
- Psychopharmacological aspects of sleep and chronobiology
- Neuroimaging and psychoactive drugs
- Phytopharmacology and psychoactive substances
- Drug treatment of neurological disorders
- Mechanisms of action of psychotropic drugs
- Ethnopsychopharmacology
- Pharmacogenetic aspects of mental illness and drug response
- Psychometrics: psychopharmacological methods and experimental design

Human Psychopharmacology comprises Original Articles, Short Communications (not exceeding 1500 words), Reviews, Letters to the Editor (not exceeding 500 words), and Book Reviews. Editorials are by invitation but suggestions from readers are welcome.

EDITORIAL POLICY

The Editorial policy is to publish contributions on all aspects of psychopharmacology relevant to human experimental research and clinical medicine. *Human Psychopharmacology* is a multi-disciplinary journal that covers all aspects from clinical and social issues to experimental laboratory based studies that are of relevance to clinical psychopharmacology. All articles are strictly refereed and only those meeting acceptable ethical standards governing experimentation on humans or animals will be considered for publication. The editors are particularly pleased to consider publishing the proceedings of symposia as supplements to the journal providing they meet the strict editorial criteria. It is the intention of the Editors to publish contributions within three to six months from the date of final acceptance.

Human Psychopharmacology

Subscriptions

Human Psychopharmacology (Print ISSN 0885-6222; Online ISSN 1099-1077 at Wiley InterScience, www.interscience.wiley.com) is published bi-monthly plus one additional issue in April and one in August (total 8 issues) by John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.

Subscription Rates

Volume 21 2006 8 issues

Print only: US$1380.00
Electronic only: US$1380.00
A combination price of US$1518.00 includes the subscription in both print and electronic formats.

To subscribe, please contact Journals Subscriptions Department, John Wiley & Sons, Ltd., 1 Oldlands Way, Bognor Regis, West Sussex PO22 9SA, UK.
Tel: +44 (0) 1243 843335,
Fax: +44 (0) 1243 843232,
e-mail: cs-journals@wiley.co.uk

Sample Copies

If you are interested in subscribing, you may obtain a free sample copy by contacting John Wiley & Sons, Ltd. at the above address.

Services

Advertisements

Advertisement Sales Department, John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.
Tel: +44 (0)1243 770254
Fax: +44 (0)1243 770432
e-mail: adsales@wiley.co.uk

Reprints (minimum quantity 100 copies)

Reprints Co-ordinator, John Wiley & Sons, Ltd., The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.
Tel: +44 (0) 1243 770515
Fax: +44 (0) 1243 770144
E-mail: reprints@wiley.co.uk

General Enquiries

Tel: +44 (0) 1243 779777,
Fax: +44 (0) 1243 775878.

Copyright

Copyright © 2006 John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as described below, without the permission in writing of the Publisher.

Copying of articles is not permitted except for personal and internal use, to the extent permitted by national copyright law, or under the terms of a licence issued by the national Reproduction Rights Organization (such as Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 9HE, UK or Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970, USA). The price per copy is $30.00. Requests for permission for other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale, and other enquiries should be addressed to the Publisher.

Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinions of John Wiley & Sons, Ltd. Wiley assumes no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. Wiley expressly disclaims any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought.

Abstracting and Indexing

Human Psychopharmacology is covered by the following abstracting and indexing services: Biological Abstracts® (Thomson ISI), CAB Abstracts® (CABI), Cambridge Scientific Abstracts (CIG), Chemical Abstracts Service (ACS), Current Abstracts (EBSCO), Current Awareness in Biological Sciences (Elsevier), Current Contents®/Life Sciences (Thomson ISI), EMBASE/Excerpta Medica (Elsevier), Index Medicus/MEDLINE/PubMed (NLM), Mental Health Abstracts (Kluwer), Neuroscience Citation Index™ (Thomson ISI), Psychological Abstracts/PsycINFO (APA), Science Citation Index® (Thomson ISI), Science Citation Index Expanded™ (Thomson ISI), SCOPUS (Elsevier) and SIIC Databases (Sociedad Iberoamericana de Informacion Cientifica).

Production Information

For manuscripts that have been accepted for publication, please. contact:

Robert Huston
e-mail: rhuston@wiley.co.uk

Production Details

Printed on acid-free paper
Typeset by Thomson Press (India) Ltd.
Printed and bound in Great Britain by Bell & Bain Ltd., Glasgow

Identification Statement

Human Psychopharmacology (ISSN 08856222) is published monthly except in the months of February, May, September and November by John Wiley & Sons, Ltd., The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK. Annual Subscription price US$900.00. Air freight and mailing in the USA by Publications Expediting Inc., 200 Meacham Ave., Elmont NY 11003. Periodical Postage paid at Jamaica NY 11431.
POSTMASTER please send address changes to *Human Psychopharmacology*, Publications Expediting Inc., 200 Meacham Ave., Elmont NY 11003.

CONTENTS

Volume 21 Issue Nos 1–8

HUMAN PSYCHOPHARMACOLOGY

Issue No. 1 January 2006

Research Articles

Pharmacological management of behavioural and psychological disturbance in dementia: **M. N. Kozman, J. Wattis and S. Curran** 1

Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers: **M. J. Barbanoj, C. García-Gea, R. Antonijoan, I. Izquierdo, E. Donado, I. Pérez, A. Solans and F. Jané** 13

Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults: **N. R. Burns, J. Bryan and T. Nettelbeck** 27

Acute effect of isometric exercise on desire to smoke and tobacco withdrawal symptoms: **M. Ussher, R. West, R. Doshi and A. K. Sampuran** 39

Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function: **P. J. Nathan, R. Segrave, K. L. Phan, B. O'Neill and R. J. Croft** 47

Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment: **H. Herken, O. Akyol, H. R. Yilmaz, H. Tutkun, H. A. Savas, M. E. Ozen, A. Kalenderoglu and M. Gulec** 53

Letter to the Editor

Trazodone-induced cardiac arrhythmias: a report of two cases: **D. Winkler, R. Ortner, E. Pjrek, H. Aschauer and S. Kasper** 61

Book Review

Clinical Geriatric Psychopharmacology (4th Edition): **S. Curran** 63

Current Awareness 65

Issue No. 2 March 2006

Reviews

Reviewing the use of antipsychotic drugs in people with intellectual disability: **G. La Malfa, S. Lassi, M. Bertelli and A. Castellani** 73

Dopamine challenge tests as an indicator of psychological traits: **P. Netter** 91

Research Articles

Diazepam-induced prospective memory impairment and its relation to retrospective memory, attention, and arousal: **J. B. Rich, E. Svoboda and G. G. Brown** 101

Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action: **M. G. Uzbekov, E. Y. Misionzhnik, N. M. Maximova and O. P. Vertogradova** 109

Review

A systematic review of the serotonergic effects of Mirtazapine in humans: implications for its dual action status: **P K. Gillman** 117

Letter to the Editor

Galantamine may improve attention and speech in schizophrenia: **E. L. M. Ochoa and E. Clark** 127

Current Awareness 129

Issue No. 3 April 2006

Research Articles

Efficacy of etifoxine compared to lorazepan monotherapy in the treatment of patients with adjustment disorders with anxiety: **a double-blind controlled study in general practice: N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M.-E. Le Guern, J. Micallef and O. Blin** 139

Mirtazapine naturalistic depression study (in Sweden)—MINDS(S): clinical efficacy and safety: **J. Wålinder, J. Prochazka, A. Odén, I. Sjöden, M.-L. Dahl, J. Ahlner and F. Bengtsson** 151

ALDH2 genotype-associated differences in the acute effects of alcohol on P300, psychomotor performance, and subjective response in healthy young Korean men: a double-blind placebo-controlled crossover study: **H.-Y. Shin, I.-S. Shin and J.-S. Yoon** 159

Acute effects of caffeine in volunteers with different patterns of regular consumption: **P. Hewlett and A. Smith** 167

A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters: **P. Leombruni, A. Pierò, A. Brustolin, V. Mondelli, M. Levi, S. Campisi, S. Marozio, G. Abbate-Daga and S. Fassino** 181

Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both: **F. Centorrino, J. Hennen, G. Mallya, S. Egli, T. Clark and R. J. Baldessarini** 189

Review

Statistical methodologies in psychopharmacology: a review: **P. Nieminen, J. Miettunen, H. Koponen and M. Isohanni** 195

Book Review

Drug Interactions in Psychiatry 3rd Edn: **B. E. Leonard** 205

Current Awareness 207

Issue No. 4 June 2006

Research Articles

A ^{1}HMRS study of the anterior cingulate gyrus in euthymic bipolar patients: **J. A. de M. S. Amaral, R. S. Tamada, C. K. Issler, S. C. Caetano, G. G. Cerri, C. C. de Castro and B. Lafer** 215

Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis: **A. H. Farabaugh, S. B. Sonawalla, M. Fava, P. Pedrelli, G. I. Papakostas, F. Schwartz and D. Mischoulon** 221

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia: **P. Sirota, I. Pannet, A. Koren and E. Tchernichovsky** 227

Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: A naturalistic prospective 12-week observational study: **R. D. Strous, M. Kupchik, S. Roitman, S. Schwartz, N. Gonen, R. Mester, A. Weizman and B. Spivak** 235

Review

Cannabis and neurodevelopment: implications for psychiatric disorders: **S. Sundram** 245

Research Articles

Patterns of simultaneous polysubstance use in drug using university students: **S. P. Barrett, C. Darredeau and R. O. Pihl** 255

The role of the standard EEG in clinical psychiatry: **S. S. O'Sullivan, G. M. Mullins, E. M. Cassidy and B. McNamara** 265

Book Review

Handbook of Psychiatric Drug Therapy: **B. E. Leonard** 273

Current Awareness 275

Issue No. 5 July 2006

Research Articles

Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users: **A. C. Parrott, J. Rodgers, T. Buchanan, J. Ling, T. Heffernan and A. B. Scholey** 285

A high sugar content, low caffeine drink does not alleviate sleepiness but may worsen it: **C. Anderson and J. A. Horne** 299

Functional cognitive assessment scale (FUCAS): a new scale to assess executive cognitive function in daily life activities in patients with dementia and mild cognitive impairment: **F. Kounti, M. Tsolaki and G. Kiosseoglou** 305

Safety and efficacy of rapid dose administration of quetiapine in bipolar mania: **A. Hatim, H. Habil, S. G. Jesjeet, C. C. Low, J. Joseph, S. T. Jambunathan and N. Z. Zuraida** 313

Do benzodiazepines extend the duration of follow-up treatment in patients with bipolar disorder?: **G. Hwang, H.-R. Kim, S.-H. Park, S.-H. Kim, S.-R. Park and G.-H. Kim** 319

Effects of a benzodiazepine on free recall of semantically related words: **A. M. L. Nogueira, S. Pompéia, J. C. F. Galduróz and O. F. A. Bueno** 327

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study: **C. Akkaya, E. Y. Sivrioglu, S. Akgoz, S. S. Eker and S. Kirli** 337

Current Awareness 347

Issue No. 6 August 2006

Research Articles

The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic?: **J. E. Fisk, C. Montgomery, M. Wareing and P. N. Murphy** 355

Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence: **A. A. Patkar, P. Mannelli, K. P. Hill, K. Peindl, C. Pae and T. H. Lee** 367

Stress reactivity: biological and subjective responses to the cold pressor and Trier Social stressors: **A. L. McRae, M. E. Saladin, K. T. Brady, H. Upadhyaya, S. E. Back and M. A. Timmerman** 377

Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?: **B.-J. Kang, M.-J. Cho, J.-T. Oh, Y. Lee, B.-J. Chae and J. Ko** 387

Plasma concentrations of high-dose olanzapine in a double-blind crossover study: **D. L. Kelly, C. M. Richardson, Y. Yu and R. R. Conley** 393

Long-term treatment with long-acting risperidone in Korean patients with schizophrenia: **M.-S. Lee, Y.-H. Ko, S.-H. Lee, Y.-J. Seo, S.-H. Kim, S.-H. Joe, C.-S. Han, J.-H. Lee and I.-K. Jung** 399

Short Communication

Pharmacokinetic parameters of bromperidol in Korean subjects: **S.-Y. Lee, Y. G. Kim, H.-G. Kim and J.-W. Kim** 409

Book Reviews

2005-2006 Prescribing Guidelines – 8th Edition: **B. E. Leonard** 413

Cannabis Dependence: its nature, consequences and treatment: **B. E. Leonard** 414

Current Awareness 415

Issue No. 7 October 2006

Research Articles

Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity: **R. Kotwal, A. Guerdjikova, S. L. McElroy and P. E. Keck Jr.** 425

Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders: **R. Yoshimura, Y. Nakano, H. Hori, A. Ikenouchi, N. Ueda and J. Nakamura** 433

Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms: **T. Taniguchi, S. Sumitani, M. Aon, J. Iga, S. Kinouchi, H. Aki, M. Matsushita, K. Taniguchi, M. Tsuno, K. Yamanishi, M. Tomotake, Y. Kaneda and T. Ohmori** 439

Case Report

A case series of patients with Tourette's Syndrome in the United Kingdom treated with aripiprazole: **L. Davies, J. S. Stern, N. Agrawal and M. M. Robertson** 447

Research Articles

Schizotypy, marijuana, and differential item functioning: **M. Earleywine** 455

Is the loudness dependence of auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy subjects?: **I. Uhl, I. Gorynia, J. Gallinat, C. Mulert, A. Wutzler, A. Heinz and G. Juckel** 463

Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant: **M. Wingen, S. Langer and J. G. Ramaekers** 473

Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study: **A. Collie, P. Maruff, P. J. Snyder, M. A. Darekar and J. P. Huggins** 481

Book Reviews

Advances in Neurology. Volume 99. Tourette Syndrome: **A. S. Al-Din** 489

Depression and Brain Dysfunction: **B. E. Leonard** 490

Atypical antipsychotics—From Bench to Bedside: **B. E. Leonard** 492

Handbook of Psychiatric Drugs: **B. E. Leonard** 492

Current Awareness in Human Psychopharmacology 493

Issue No. 8 December 2006

Research Articles

An investigation of the long-term benefits of antidepressant medication in the recovery of patients with chronic fatigue syndrome: **M. A. Thomas and A. P. Smith** 503

Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study: **B. P. Murphy, A. H. Stuart, D. Wade, S. Cotton and P. D. McGorry** 511

Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study: **E. Kim, K.-S. Yu, J.-Y. Cho, Y.-W. Shin, S. Y. Yoo, Y. Y. Kim, I.-J. Jang, S.-G. Shin and J. S. Kwon** 519

Short Communication

Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite: **K. I. Melkersson** 529

Short Report

Survey of medication adherence in patients with schizophrenia—Korean ADHES data: **S.-W. Kim, J.-S. Yoon and S.-K. Choi** 533

Research Articles

Nicotine self-administration: cigarette versus nicotine gum diurnal topography: **M. Mooney, C. Green and D. Hatsukami** 539

Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers: **D. M. Penetar, A. R. Looby, Z. Su, L. H. Lundahl, M. Erös-Sarnyai, J. F. McNeil and S. E. Lukas** 549

Book Review

The chemical languages of the nervous system: History of scientists and substances: **K. J. Netter and P. Netter** 560

Erratum 562

Current Awareness 563

Author Index 575

Keyword Index 577

Volume Contents iii